Skip to main content
SpringerLink
Log in

Intermittent or continuous transdermal nitroglycerin: Still an issue, or Is the case closed?

  • Editorial Comment
  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Summary

After a decade of controversy and debate, many experts have now concluded that continous nitroglycerin patch treatment leads to complete tolerance development and therefore cannot be recommended for any angina patient. This conclusion is largely based on the disappointing results of the large Transdermal Nitroglycerin Cooperative Study, in which continuous patch treatment in doses of 15–105 mg daily failed to increase exercise duration more than placebo after 2 and 8 weeks of treatment. However, other well-designed studies recently reported maintained efficacy during continuous treatment, and the differences in results has remained unexplained. The disagreeing data may be better understood if certain facts are considered: (1) The cooperative study tested a patient population with a very low first-dose treatment response-only 34 seconds (or 10–12%) improvement compared with placebo. At the end of the study, 25% of the patients terminated exercise for reasons other than angina, and a reduced nitrate responsiveness had developed, even in the placebo group. (2) Patients who demonstrate a large first-dose nitrate responsiveness tend to be less susceptible to tolerance development. (3) Even during continuous therapy, maintained efficacy is often observed in exercise tests done 2–5 hours after patch renewal, while typically no effect is seen at the end of the application period. Attenuation of the initial effects is seen with all long-acting nitrate treatment regimens, but the degree of tolerance varies with the patient population, the efficacy parameter (exercise test vs. attack counts), the timing of the efficacy test, the patch dose, and whether or not nitrate-free (-low) intervals are used. In general, intermittent patch therapy is superior to continuous therapy in improving exercise duration, but even continuous therapy may retain some effect. Rebound phenomena do occur but are clinically relevant only in a minority of the patients. Rebound phenomena are not a problem during continuous therapy, which therefore may be of value in patients with frequent and/or nocturnal angina attacks. Patients experiencing angina during exercise only and with low first-dose effects are likely to benefit more from intermittent therapy. Doses of 0.6–0.8 mg/hr (15–20 mg/24 hr) are usually optimal, and the efficacy is comparable with that observed after oral nitrates.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Parker JO, Fung HL. Transdermal nitroglycerin in angina pectoris. Am J Cardiol 1984; 54:471–476.

    Article  PubMed  CAS  Google Scholar 

  2. Reichek N, Priest C, Zimrin D, Chandler T, Sutton MS. Antianginal effects of nitroglycerin patches. Am J Cardiol 1984;54:1–7.

    Article  PubMed  CAS  Google Scholar 

  3. Crean PA, Ribeiro P, Crea F, Davies GJ, Ratcliffe D, Maseri A. Failure of transdermal nitroglycerin to improve chronic stable angina: A randomized, placebo-controlled, double-blind, double crossover trial. Am Heart J 1984;108:1494–1500.

    Article  PubMed  CAS  Google Scholar 

  4. Wiesenberg G, Roks C, Nichol P, Goddard MD. Sustained effect of and lack of development of tolerance to controlled release isosorbide-5-mononitrate in chronic stable angina pectoris. Am J Cardiol 1989;64:569–576.

    Article  Google Scholar 

  5. Parker JO. Controlled release isosorbide-5-mononitrate in angina pectoris: A comparison with standard formulation isosorbide dinitrate. Can J Cardiol 1991;7:125–130.

    PubMed  CAS  Google Scholar 

  6. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium in 58,050 patients with suspected acute myocardial infarction. Lancet 1995;345:669–685.

    Article  Google Scholar 

  7. Chrysant SG, Glasser SP, Bittar N, et al. Efficacy and safety of extended-release isosorbide mononitrate for stable effort angina pectoris. Am J Cardiol 1993;72:1249–1256.

    Article  PubMed  CAS  Google Scholar 

  8. Thadani U, Lipicky RJ. Short and long-acting oral nitrates for stable angina pectoris. Cardiovasc Drugs Ther 1994;8: 611–623.

    Article  PubMed  CAS  Google Scholar 

  9. Nissinen A, Wiklund I, Lahti T, et al. Anti-anginal therapy and quality of life. A comparison of the effects of transdermal nitroglycerin and long-acting oral nitrates. J Clin Epidemiol 1991;44:989–997.

    Article  PubMed  CAS  Google Scholar 

  10. Thadani U, Lipicky RJ. Ointments and transdermal nitroglycerin patches for stable angina pectoris. Cardiovasc Drugs Ther 1994;8:625–633.

    Article  PubMed  CAS  Google Scholar 

  11. Frishman WH. Tolerance, rebound and time-zero effect of nitrate therapy. Am J Cardiol 1992;70:43G-48G.

    Article  PubMed  CAS  Google Scholar 

  12. Fletcher A. Transdermal nitroglycerin. Does it really work in the treatment of angina? Drugs Aging 1991;1:6–16.

    PubMed  CAS  Google Scholar 

  13. Mangione NJ, Glasser SP. Phenomenon of nitrate tolerance. Am Heart J 1994;128:137–146.

    Article  PubMed  CAS  Google Scholar 

  14. Steering Committee, Transdermal Nitroglycerin Cooperative Study. Acute and chronic efficacy of continuous twenty-four-hour application of transdermal nitroglycerin. Am J Cardiol 1991;68:1263–1273.

    Article  Google Scholar 

  15. Demots H, Glasser SP. Intermittent transdermal nitroglycerin therapy in the treatment of chronic stable angina. J Am Coll Cardiol 1989;13:786–793.

    PubMed  CAS  Google Scholar 

  16. Luke R, Sharpe N, Coxon R. Transdermal nitroglycerin in angina pectoris: Efficacy of intermittent application. J Am Coll Cardiol 1987;10:642–646.

    PubMed  CAS  Google Scholar 

  17. Muiesan ML, Agabiti-Rosei E, Romanelli G, et al. Transdermal nitroglycerin efficacy in patients with chronic stable angina pectoris as related to sympathetic and reninangiotensin-aldosterone activity. Eur Heart J 1992;13: 15–21.

    PubMed  CAS  Google Scholar 

  18. Greco R, D'Alterio D, Schiattarella M, Boccia A, Greco L, Marsica F. Efficacy of a new transdermal nitroglycerin patch (Deponit 10) for stable angina pectoris. Am J Cardiol 1988;61:44E-51E.

    Article  PubMed  CAS  Google Scholar 

  19. Scardi S, Pandullo C, Pivotti F, Cesschia G, Pollavini G. Individual responses to transdermal nitrates after chronic administration in angina pectoris. Int J Cardiol 1988;21: 21–32.

    Article  PubMed  CAS  Google Scholar 

  20. Milliano PA, Koster RW, Bär FW, et al. Long-term efficacy of continuous and intermittent use of transdermal nitroglycerin in stable angina pectoris. Am J Cardiol 1991;68: 857–862.

    Article  PubMed  Google Scholar 

  21. Dickstein K, Knutsen H. A double blind multiple crossover trial evaluating a transdermal nitroglycerin system versus placebo. Eur Heart J 1985;6:50–56.

    PubMed  CAS  Google Scholar 

  22. Shell WE, Dobson D. Dissociation of exercise tolerance and total myocardial ischemic burden in chronic stable angina pectoris. Am J Cardiol 1990;66:42–48.

    Article  PubMed  CAS  Google Scholar 

  23. Ferratini M, Pirelli S, Merlini P, Silva P, Pollavini G. Intermittent transdermal nitroglycerin monotherapy in stable exercise-induced angina: A comparison with a continuous schedule. Eur Heart J 1989;10:998–1002.

    PubMed  CAS  Google Scholar 

  24. Naito H, Matsuda Y, Yorozu T, et al. Effects of sublingual nitroglycerin in patients receiving transdermal nitroglycerin for coronary artery disease: Prevention of cross-tolerance. Clin Cardiol 1991;14:644–650.

    Article  PubMed  CAS  Google Scholar 

  25. Klemsdal TO, Gjesdal K. The effect of transdermal nitroglycerin on exercise tolerance in relation to patch application time—A meta-analysis. Cardiovasc Drugs Ther 1992;6: 641–649.

    Article  PubMed  CAS  Google Scholar 

  26. Reiniger G, Menke G, Boertz A, Kraus F, Rudolph W. Intervalltherapi zur effektiven Behandlung der Angina Pectoris mit Nitroglycerin-Pflastersystemen. Herz 1987;12: 68–73.

    PubMed  CAS  Google Scholar 

  27. Thadani U, Bittar N. Effects of 8:00 a.m. and 2:00 p.m. doses of isosorbide-5-mononitrate during twice daily therapy in stable angina pectoris. Am J Cardiol 1992;70: 286–292.

    Article  PubMed  CAS  Google Scholar 

  28. Nyberg G, Carlens P, Lindstrøm E, et al. The effect of isosorbide-5-mononitrate (5-ISMN) Durules® on exercise tolerance in patients with exertional angina pectoris. A placebo controlled study. Eur Heart J 1986;7:835–842.

    PubMed  CAS  Google Scholar 

  29. Svendsen JH, Aldershvile J, Abildgaard U, Amtorp O. Efficacy of controlled release isosorbide-5-mononitrate as adjunctive treatment to β-blocking agents in patients with stable angina pectoris. J Cardiovasc Pharmacol 1989;14: 358–363.

    Article  PubMed  CAS  Google Scholar 

  30. Seabra-Gomes R, Aleixo AM, Adao M, et al. Comparison of the effects of a controlled-release formulation of isosorbide-5-mononitrate and conventional isosorbide dinitrate on exercise performance in men with stable angina pectoris. Am J Cardiol 1990;65:1308–1312.

    Article  PubMed  CAS  Google Scholar 

  31. Cowan JC, Bourke JP, Reid DS, Julian DG. Prevention of tolerance to nitroglycerin patches by overnight removal. Am J Cardiol 1987;60:271–275.

    Article  PubMed  CAS  Google Scholar 

  32. Gumbrielle T, Freedman SB, Fogarty L, Ogasawara S, Kelly DT. Efficacy, safety, and duration of nitrate-free interval to prevent tolerance to transdermal nitroglycerin in effort angina. Eur Heart J 1992;13:671–678.

    PubMed  CAS  Google Scholar 

  33. Rosetti E, Luca C, Bonetti F, Chierchia SL. Transdermal nitroglycerin reduces frequency of anginal attacks, but fails to prevent silent ischemia. J Am Coll Cardiol 1993;21: 337–342.

    Google Scholar 

  34. Scardi S, Camerini F, Pandullo G, Pollavini P and the Collaborative Nitro Group. Efficacy of continuous and intermittent transdermal treatment with nitroglycerin in effort angina pectoris: A multicentric study. Int J Cardiol 1991;32:241–248.

    Article  PubMed  CAS  Google Scholar 

  35. Greco R, Schiattarella M, Wolff S, D'Altero D, Tartaglia P. Long-term efficacy of nitroglycerin patch in stable angina pectoris. Am J Cardiol 1990;65:9J–15J.

    Google Scholar 

  36. Sullivan M, Savvides M, Aboantoun S, Madsen B, Froelicher V. Failure of transdermal nitroglycerin to improve exercise capacity in patients with angina pectoris. J Am Coll Cardiol 1985;5:1220–1223.

    PubMed  CAS  Google Scholar 

  37. Thadani U, Hamilton SF, Olson E, et al. Transdermal nitroglycerin patches in angina pectoris. Ann Intern Med 1986; 105:485–492.

    PubMed  CAS  Google Scholar 

  38. Gibelli G, Negrini M, Bruno AM, et al. Chronic effects of transdermal nitroglycerin in stable angina pectoris: A within patient, placebo-controlled study. Int J Clin Pharmacol Ther Toxicol 1989;27:436–441.

    PubMed  CAS  Google Scholar 

  39. Frishman WH, Giles T, Greenberg S, et al. Sustained high-dose nitroglycerin transcutaneous patch therapy in angina pectoris: Evidence for attenuation of effect over time. J Clin Pharmacol 1989;29:1097–1105.

    PubMed  CAS  Google Scholar 

  40. James MA, Papouchado M, Jones JV. Attenuation of nitrate effect during an intermittent treatment regimen and the time course of nitrate tolerance. Eur Heart J 1991;12: 1266–1272.

    PubMed  CAS  Google Scholar 

  41. Waters DD, Juneau M, Gossard D, Choquette G, Brien M. Limited usefulness of intermittent nitroglycerin patches in stable angina. J Am Coll Cardiol 1989;13:421–425.

    PubMed  CAS  Google Scholar 

  42. Schaer DH, Buff LA, Katz RJ. Sustained antianginal efficacy of transdermal nitroglycerin patches using an over-night 10-hour nitrate-free interval. Am J Cardiol 1988;61: 46–50.

    Article  PubMed  CAS  Google Scholar 

  43. Parker JO, Amies MH, Hawkinson RW, et al. Intermittent transdermal nitroglycerin therapy in angina pectoris. Clinically effective without tolerance or rebound. Circulation 1995;91:1368–1374.

    PubMed  CAS  Google Scholar 

  44. Nabel EG, Barry J, Rocco MB, Mead K, Selwyn AP. Effects of dosing intervals on the development of tolerance to high dose transdermal nitroglycerin. Am J Cardiol 1989;63: 663–669.

    Article  PubMed  CAS  Google Scholar 

  45. Fox KM, Dargie HJ, Deanfield J, Maseri A. Avoidance of tolerance and lack of rebound with intermittent dose titrated transdermal glyceryl trinitrate. Br Heart J 1991;66: 151–155.

    Article  PubMed  CAS  Google Scholar 

  46. Holdright DR, Katz RJ, Wright CA, et al. Lack of rebound during intermittent transdermal treatment with glyceryl trinitrate in patients with stable angina on background beta blocker. Br Heart J 1993;69:223–227.

    Article  PubMed  CAS  Google Scholar 

  47. Parker JD, Parker AB, Farell B, Parker JO. Intermittent transdermal nitroglycerin therapy. Decreased anginal threshold during the nitrate-free interval. Circulation 1995; 91:973–978.

    PubMed  CAS  Google Scholar 

  48. Parker JD, Farell B, Fenton T, Cohanim M, Parker JO. Counter-regulatory responses to continuous and intermittent therapy with nitroglycerin. Circulation 1991;84: 2336–2345.

    PubMed  CAS  Google Scholar 

  49. Dupuis J, Lalonde G, Lemieux R, Rouleau JL. Tolerance to intravenous nitroglycerin in patients with congestive heart failure: Role of increased vascular volume, neurohumoral activation and lack of prevention with N-acetylcystein. J Am Coll Cardiol 1990;16:923–931.

    Article  PubMed  CAS  Google Scholar 

  50. Freedman SB, Daxini BP, Noyce D, Kelly DT. Intermittent transdermal nitrates do not improve ischemia in patients taking beta-blockers or calcium antagonists: Potential role of rebound ischemia during the nitrate-free period. J Am Coll Cardiol 1995;25:349–355.

    Article  PubMed  CAS  Google Scholar 

  51. Imhof PR, Ott B, Frankhauser P, Chu LC, Hodler J. Difference in nitroglycerin dose-response in the venous and arterial beds. Eur J Clin Pharmacol 1980;18:455–460.

    Article  PubMed  CAS  Google Scholar 

  52. Bassenge E. Nitrates in different vascular beds, nitrate tolerance, and interaction with endothelial function. Am J Cardiol 1992;70:23B-29B.

    Article  PubMed  CAS  Google Scholar 

  53. Leier CV, Huss P, Raymond RN, Magorien D, Unverferth DV. Improved exercise capacity and differing arterial and venous tolerance during chronic isosorbide dinitrate therapy for congestive heart failure. Circulation 1983;67: 817–822.

    PubMed  CAS  Google Scholar 

  54. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: Results of a Veteran Administration Cooperative Study. N Engl J Med 1986;314:1547–1552.

    PubMed  CAS  Google Scholar 

  55. Thadani U, Fung HL, Darke AC, et al. Oral isosorbide dinitrate in angina pectoris: Comparison of duration of action and dose response relation during acute and sustained therapy. Am J Cardiol 1982;49:411–419.

    Article  PubMed  CAS  Google Scholar 

  56. Muiesan G, Agabiti-Rosei E, Muiesan L, et al. A multicenter trial of transdermal nitroglycerin in exercise-induced angina: Individual anti-anginal response after repeated administration. Am Heart J 1986;112:233–238.

    Article  PubMed  CAS  Google Scholar 

  57. Paciaroni E, Luca C. Discontinuous transdermal nitroglycerin as treatment for stable angina in the elderly: A double-blind multicentre study. Eur Heart J 1991;12:1076–1080.

    PubMed  CAS  Google Scholar 

  58. Noonan PK, Gonzales MA, Ruggirello D, et al. Relative bioavailability of a new transdermal nitroglycerin delivery system. J Pharm Sci 1986;75:688–691.

    Article  PubMed  CAS  Google Scholar 

  59. Barkve TF, Langseth-Manrique K, Bredesen JE, Gjesdal K. Increased uptake of transdermal glyceryl trinitrate during physical exercise and during high ambient temperature. Am Heart J 1986;112:537–541.

    Article  PubMed  CAS  Google Scholar 

  60. Parker JO. Eccentric dosing with isosorbide-5-mononitrate in angina pectoris. Am J Cardiol 1993;72:871–876.

    Article  PubMed  CAS  Google Scholar 

  61. Thadani U, Maranda CR, Amsterdam E, et al. Lack of pharmacologic tolerance and rebound angina pectoris during twice-daily therapy with isosorbide-5-mononitrate. Ann Intern Med 1994;120:353–359.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiology, Ullevål University Hospital, Oslo, Norway

    T. O. Klemsdal

  2. Department of Clinical Physiology, Oslo, Norway

    K. Gjesdal

Authors
  1. T. O. Klemsdal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. Gjesdal
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Klemsdal, T.O., Gjesdal, K. Intermittent or continuous transdermal nitroglycerin: Still an issue, or Is the case closed?. Cardiovasc Drug Ther 10, 5–10 (1996). https://doi.org/10.1007/BF00051124

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00051124

Key Words

Search

Navigation